sparsentan

Sparsentan is a first-in-class, orally active small molecule that acts as a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R). It is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. By blocking both ETAR and AT1R, sparsentan inhibits two key pathways involved in kidney disease progression—endothelin-1 and angiotensin II signaling—resulting in anti-inflammatory, antifibrotic, and hemodynamic protective effects on the kidney. Sparsentan was developed by merging structural elements from irbesartan (AT1R antagonist) and biphenylsulfonamide (ETAR antagonist). The drug is approved under accelerated approval based on its ability to reduce proteinuria[1][2][6][8].

Brand names

Filspari

Other names

sparsentan